195 related articles for article (PubMed ID: 28398414)
21. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
22. ACOG Committee Opinion Number 540: Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills.
Committee on Gynecologic Practice
Obstet Gynecol; 2012 Nov; 120(5):1239-42. PubMed ID: 23090561
[TBL] [Abstract][Full Text] [Related]
23. New developments in hormonal therapy for acne.
Tan JK
Skin Therapy Lett; 2007 Sep; 12(7):1-3. PubMed ID: 17940710
[TBL] [Abstract][Full Text] [Related]
24. A survey on monopolar radiofrequency treatment.
Suh DH; Hong ES; Kim HJ; Lee SJ; Kim HS
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28805286
[TBL] [Abstract][Full Text] [Related]
25. Differences in acne therapy prescribing patterns between dermatologists and pediatricians: A population-based study.
Jones ME; Pourali SP; Kohn AH; Gutierrez Y; Rajkumar JR; Armstrong AW
Pediatr Dermatol; 2021 Sep; 38(5):1150-1156. PubMed ID: 34514637
[TBL] [Abstract][Full Text] [Related]
26. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.
Heinemann K; Heinemann LA
J Fam Plann Reprod Health Care; 2011 Jul; 37(3):132-5. PubMed ID: 21659330
[No Abstract] [Full Text] [Related]
27. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
Vinogradova Y; Coupland C; Hippisley-Cox J
BMJ; 2015 May; 350():h2135. PubMed ID: 26013557
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
Krunic A; Ciurea A; Scheman A
J Am Acad Dermatol; 2008 Jan; 58(1):60-2. PubMed ID: 17964689
[TBL] [Abstract][Full Text] [Related]
29. Dermoscopy use by Canadian dermatologists and dermatology residents: a cross-sectional nationwide study.
Burbidge T; Davidson W; Robertson L
Br J Dermatol; 2017 Nov; 177(5):e213-e214. PubMed ID: 28449184
[No Abstract] [Full Text] [Related]
30. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
Koltun W; Maloney JM; Marr J; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):171-5. PubMed ID: 21288628
[TBL] [Abstract][Full Text] [Related]
31. Depression screening at visits for acne in the United States, 2005-2016.
Taylor MT; Barbieri JS
J Am Acad Dermatol; 2020 Sep; 83(3):936-938. PubMed ID: 31972260
[No Abstract] [Full Text] [Related]
32. Yasmin--an oral contraceptive with a new progestin.
Med Lett Drugs Ther; 2002 Jun; 44(1133):55-7. PubMed ID: 12080274
[No Abstract] [Full Text] [Related]
33. Should dermatologists prescribe hormonal contraceptives for acne?
Harper JC
Dermatol Ther; 2009; 22(5):452-7. PubMed ID: 19845722
[TBL] [Abstract][Full Text] [Related]
34. Relationship between self-efficacy and patient knowledge on adherence to oral contraceptives using the Morisky Medication Adherence Scale (MMAS-8).
Tomaszewski D; Aronson BD; Kading M; Morisky D
Reprod Health; 2017 Sep; 14(1):110. PubMed ID: 28874178
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Topical Corticosteroid Prescribing, Counseling, and Communication Among Dermatologists and Pharmacists.
Millard AN; Stratman EJ
JAMA Dermatol; 2019 Jul; 155(7):838-843. PubMed ID: 30916731
[TBL] [Abstract][Full Text] [Related]
36. A nationwide study of acne treatment patterns in Korea: analysis of patient preconceived notions and dermatologist suggestion for treatment.
Kwon HH; Yoon HS; Suh DH; Yoon JY; Park SK; Lee ES; Lee JH; Kim NI; Kye YC; Ro YS; Lee SJ; Kim MN; Sung KJ; Lee ES; Kim KJ;
Acta Derm Venereol; 2012 May; 92(3):236-40. PubMed ID: 22367348
[TBL] [Abstract][Full Text] [Related]
37. Differences in acne treatment prescribing patterns of pediatricians and dermatologists: an analysis of nationally representative data.
Yentzer BA; Irby CE; Fleischer AB; Feldman SR
Pediatr Dermatol; 2008; 25(6):635-9. PubMed ID: 19067874
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of prescribing patterns of tetracycline class antibiotics and spironolactone between advanced practice providers and physicians in the treatment of acne vulgaris.
Guzman AK; Barbieri JS
J Am Acad Dermatol; 2021 Apr; 84(4):1119-1121. PubMed ID: 32561369
[No Abstract] [Full Text] [Related]
39. Prescribing isotretinoin in the United States for transgender individuals: Ethical considerations.
Yeung H; Chen SC; Katz KA; Stoff BK
J Am Acad Dermatol; 2016 Sep; 75(3):648-651. PubMed ID: 27543225
[No Abstract] [Full Text] [Related]
40. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
